Skip to main content

Table 1 Clinical and biological characteristics of acute leukemia patients.

From: Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables

  AML patients ALL patients
Number/age/gender   
   Number 39 8
   Age; median (variation range) 61 (29–84) 41 (22–79)
   Male/female 21/18 6/2
Secondary leukemia   
   Previous chemotherapy 5/39 1/8
   Primary MDS 5/39  
   Chronic myeloid leukemia 1/39  
Morphological classification (FAB classification) M0 1/39 L1 5/8
  M1 7/39 L2 3/8
  M2 11/39  
  M3 2/39  
  M4 9/39  
  M5 9/39  
Membrane molecule analysis Membrane molecule expression 1: Membrane molecule phenotype: T-ALL 2/8
  CD13 31/39 ALL-B lymphocyte type 6/8
  CD 14 5/39 Subclassification 1
  CD15 14/39 - Pro-B 2
  CD33 37/39 - Pre-pre-B 2
  CD34 17/39 (stem cell marker) - B-ALL 2
Genetic abnormalities   
Number of patients examined 36 Coclusive cytogenetic analysis 3/8 Molecular analysis of bcr-abl translocation, 3 additional patients
Cytogenetic analysis 2 Normal 15/36 Normal karyotype 0
  Intermediate 13/36 Multiple abnormalities 1
  Favourable 3/36 Single, high-risk abnormalities: t(4;11)1
  Unfavourable 5/36 Philadelphia chromosom/bcr-abl translocation 1
Flt3 abnormalities No Flt3 abnormality 17/36  
  Flt3-ITD 16/36  
  Asp835 mutation 3/36  
Response to chemotherapy Patients receiving chemotherapy 23/39 Patients receiving chemotherapy 6/8
  Complete remission after first induction 9/23 Death due to primary resistance or leukemia relapse within 6 months 4/6
  1. Totally 73 AML and 16 ALL images were included in the analysis. All ALL patients had B-cell disease and two patients comprised the bcr-abl fusion product. 1Patients were classified as positive when at least 20% of the AML cells expressed the membrane molecule [55]. 2Cytogenetic abnormalities in AML cells were classified according to Wheatley et al. [56].